Heavier FTC Scrutiny Puts Pressure On Consumer Health Product Claims
This article was originally published in The Tan Sheet
Executive Summary
Attorneys say marketers should make structure/function claims with knowledge that no claims are safe from FTC scrutiny. During the Food & Drug Law Institute annual meeting, stakeholders commented on how FTC’s stance on Bayer Health Care’s Philips Colon Health will impact other claims.
You may also be interested in...
FTC Requests Drug Claim Support For Bayer Probiotic Supplement
On behalf of the FTC, DoJ alleges Bayer violated a 2007 settlement to substantiate supplement claims and asks a court to require the firm to provide two RCTs for dietary supplement claims for Phillips’ Colon Health. Trade groups rally behind the firm, arguing the requirement is unfair and illegal.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.